Data from a clinical trial of hemophilia B gene therapy with a rAAV2 vector [2,8,9] show that an increase in liver enzyme levels was associated with the generation of cytotoxic CD8 + T cell response specific for the rAAV2 capsid protein [9]. The gene discussed is CD8A; the disease is hemophilia B.